1617

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	**CELAL ALBAYRAK**	**Examiner:**	**SHENGJUN WANG**
Serial No.:	**10/028,258**	**Group Art Unit:**	**1617**
Filed:	**DECEMBER 19, 2001**		
For:	**INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES CONTAINING HYDROPHILIC ACTIVE AGENTS**	**Docket No.**	**ABS0005/US/2**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT ON May 15, 2006, THIS PAPER IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Mary C. Deutsch

RESPONSE

Dear Sir or Madam:

This communication is in response to the Non-final Office Action mailed on November 17, 2006, in regards to the above-cited patent application.

The three-month period for response expired on February 17, 2006. Applicants hereby request a three-month extension of time for responding to the Office Action, said period of response being extended from February 17, 2006 to May 17, 2006.

Enclosed with this Response are the following additional documents:

1. Terminal Disclaimer;
2. Small Entity Status Statement;
3. Power of Attorney;
4. Assignment Recordation Cover Sheet and Assignment;
5. A check in the amount of $615.00 for the fee of this three-month extension request ($510), Terminal Disclaimer ($65) and Assignment Recordation ($40); and
6. Postcard

05/19/2006 EAYALEW1 00000033 10028258
01 FC:2253 510.00 OP

If the amount submitted herewith is found to be incorrect, the Commissioner is authorized to charge any other fees, or credit any overpayment to Kagan Binder deposit account No. 50-1775 and notify us of the same.

It is believed that no other fee is required in filing this submission. However, if any fee is required, please charge the appropriate fee to the Kagan Binder Deposit Account No. 50-1775 and notify us of the same.

Kindly amend the paragraph at page 13, lines 1-7 as follows:

Once the drug phase is prepared, an aqueous surfactant phase is added to the vessel in which the drug phase is contained as detailed below. The polymer solvent is selected based on its miscibility in the aqueous surfactant phase. According to the present invention, the polymer solvent and aqueous surfactant solutions are selected based on their solubility parameters ($\delta(cal/cm^3)^{1/2}$). According to preferred embodiments, $\delta_{\text{polymer solvent}} - \delta_{\text{aqueous phase}} < 0$ preferably . $\delta_{\text{polymer solvent}} - \delta_{\text{aqueous phase}}$ is within the ~~range 0 - 15 $\delta(cal/cm^3)^{1/2}$~~ range 0 to -15 $\delta(cal/cm^3)^{1/2}$.